IRadimed Corp (NASDAQ: IRMD) is a medical device company that designs, manufactures, and sells MRI compatible IV infusion pumps and patient vital signs monitoring systems. Revenue comes from device sales, accessories, extended maintenance agreements, and services related to maintaining its products. IRadimed sells directly to U.S. hospitals, acute care facilities, and outpatient imaging centers through relationships with integrated delivery networks (IDNs) and group purchasing organizations (GPOs), and holds CE Mark certification allowing sales in the European Community. The company was founded by Roger Susi, who serves as President, CEO, and Chairman of the Board, and holds an assigned patent portfolio of 21 issued U.S. patents and 4 issued foreign patents with remaining lives of up to 19 years, as disclosed in the 10-K filed 2026-03-06. All manufacturing occurs at a single facility in Orlando, Florida.

Revenue model

Transactional sales of MRI compatible medical devices and accessories, supplemented by extended maintenance agreements and maintenance services, as disclosed in the 10-K filed 2026-03-06.

Products and services

MRidium 3870 and 3860+ MRI compatible IV infusion pump systems; IRadimed 3880 MRI compatible patient vital signs monitoring system (monitors ECG, SpO2 via Masimo algorithms, respiratory CO2, invasive and non-invasive blood pressure, temperature, and optional multi-gas anesthetic agent); fiber optic MRI SpO2 sensors and accessories. Products are designed to operate inside MRI scanner rooms in magnetic fields up to 30,000 gauss.

Customers and end markets

U.S. hospitals, acute care facilities, and outpatient imaging centers, accessed in part through IDNs and GPOs. International customers in the European Community and other markets where CE Mark certification applies.

Value-chain role

Vertically integrated manufacturer and direct seller of MRI compatible medical devices. Designs, manufactures, and sells products from a single facility in Orlando, Florida. Sells through a direct sales force and protects technology via patents, trade secrets, and confidentiality agreements.

Geographic exposure

Primary manufacturing and sales in the United States (Orlando, Florida). CE Mark certification enables sales in the European Community. ISO 13485:2016 and Medical Device Single Audit Program certifications maintained as of October 2024, with renewal required by January 2028.

Source: SEC 10-K, filed 2026-03-06

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories /entities/zyxiq AxoGen Inc Cue Health Inc. Vicarious Surgical Inc Orthofix Medical Inc Sight Sciences Inc Semler Scientific, Inc. SURMODICS INC ZimVie Inc.